A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 1, 2006, Pages 129-136

  Azzaroli, F ^a,b   Colecchi, A ^b   Lodato, F ^b   Trere D ^b   Bacchi Reggiani, M L ^b   Festi, D ^b   Prati, G M ^b   Accogli, E ^b   Casanova, S ^b   Derenzini, M ^b   Roda, E ^b   Mazzella, G ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; FERRITIN;

ADULT; AGED; ARGYROPHILIA; ARTICLE; CELL PROLIFERATION; ECHOGRAPHY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; VIRUS GENE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; FEMALE; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 33745138493     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02955.x     Document Type: Article

References (35)

1. Bosch FX Ribes J Diaz M Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004 127 ( 5 Suppl. 1 S5 S16.
2. Fattovich G Stroffolini T Zagni I Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004 127 ( 5 Suppl. 1 S35 50.
3. Bruix J Sherman M Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001 35 : 421 30.
4. Sangiovanni A Del NE Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004 126 : 1005 14.
5. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003 39 : 1076 84.
6. Lin OS Keeffe EB Sanders GD Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004 19 : 1159 72.
7. Mazzella G Accogli E Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996 24 : 141 7.
8. Sherman M Klein A. AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings. Hepatology 2004 40 : 1465 73.
9. Sangiovanni A Colombo E Radaelli F, et al. Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients. Am J Gastroenterol 2001 96 : 1575 80.
10. Donato MF Arosio E Del NE, et al. High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity. Hepatology 2001 34 : 523 8.
11. Ballardini G Groff P Zoli M, et al. Increased risk of hepatocellular carcinoma development in patients with cirrhosis and with high hepatocellular proliferation. J Hepatol 1994 20 : 218 22.
12. Trere D Borzio M Morabito A Borzio F Roncalli M Derenzini M. Nucleolar hypertrophy correlates with hepatocellular carcinoma development in cirrhosis due to HBV infection. Hepatology 2003 37 : 72 78.
13. Tarao K Ohkawa S Shimizu A, et al. Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus-positive cirrhotic patients. Cancer 1994 73 : 1149 54.
14. Pession A Farabegoli F Trere D, et al. The Ag-NOR proteins and transcription and duplication of ribosomal genes in mammalian cell nucleoli. Chromosoma 1991 100 : 242 50.
15. Sirri V Roussel P Trere D Derenzini M Hernandez-Verdun D. Amount variability of total and individual Ag-NOR proteins in cells stimulated to proliferate. J Histochem Cytochem 1995 43 : 887 93.
16. Nonomura A Mizukami Y Matsubara F Nakanuma Y. Identification of nucleolar organizer regions in non-neoplastic and neoplastic hepatocytes by the silver-staining technique. Liver 1990 10 : 229 38.
17. Crocker J McGovern J. Nucleolar organiser regions in normal, cirrhotic, and carcinomatous livers. J Clin Pathol 1988 41 : 1044 8.
18. Borzio M Trere D Borzio F, et al. Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Pathol 1998 51 : 96 101.
19. Fakan S Hernandez-Verdun D. The nucleolus and the nucleolar organizer regions. Biol Cell 1986 56 : 189 205.
20. Trere D. AgNOR staining and quantification. Micron 2000 31 : 127 31.
21. Caturelli E Castellano L Fusilli S, et al. Coarse nodular US pattern in hepatic cirrhosis: risk for hepatocellular carcinoma. Radiology 2003 226 : 691 7.
22. Desmet VJ Gerber M Hoofnagle JH Manns M Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994 19 : 1513 20.
23. Aubele M Biesterfeld S Derenzini M, et al. Guidelines of AgNOR quantitation. Committee on AgNOR Quantitation within the European Society of Pathology. Zentralbl Pathol 1994 140 : 107 8.
24. Siddiqui MS Soomro IN Kayani N Muzaffar S Hasan SH. Assessment of nucleolar organizer regions (NORs) in proliferative conditions of the liver. Pathol Res Pract 1999 195 : 421 6.
25. Velazquez RF Rodriguez M Navascues CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003 37 : 520 7.
26. Ganne-Carrie N Chastang C Chapel F, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology 1996 23 : 1112 8.
27. Makino Y Shiraki K Sugimoto K, et al. Histological features of cirrhosis with hepatitis C virus for prediction of hepatocellular carcinoma development; a prospective study. Anticancer Res 2000 20 ( 5C 3709 15.
28. Tarao K Hoshino H Shimizu A, et al. Patients with ultrasonic coarse-nodular cirrhosis who are anti-hepatitis C virus-positive are at high risk for hepatocellular carcinoma. Cancer 1995 75 : 1255 62.
29. Kitamura S Iishi H Tatsuta M, et al. Liver with hypoechoic nodular pattern as a risk factor for hepatocellular carcinoma. Gastroenterology 1995 108 : 1778 84.
30. Jezequel AM Paolucci F Benedetti A Mancini R Orlandi F. Enumeration of S-phase cells in normal rat liver by immunohistochemistry using bromodeoxyuridine-antibromodeoxyuridine system. Dig Dis Sci 1991 36 : 482 4.
31. Hall PA Levison DA Woods AL, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990 162 : 285 94.
32. Sherman M Shafritz DA. Hepatitis B virus and hepatocellular carcinoma: molecular biology and mechanistic considerations. Semin Liver Dis 1984 4 : 98 112.
33. Azzaroli F Accogli E Nigro G, et al. Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. World J Gastroenterol 2004 10 : 3099 102.
34. Fiorentino M Altimari A D'Errico A, et al. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res 2000 6 : 3966 72.
35. Cui J Dong BW Liang P Yu XL Yu DJ. Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection. World J Gastroenterol 2004 10 : 1533 6.